Eli Lilly and Company $LLY Shares Bought by Whitener Capital Management Inc.

Whitener Capital Management Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 79.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,960 shares of the company’s stock after buying an additional 1,309 shares during the period. Whitener Capital Management Inc.’s holdings in Eli Lilly and Company were worth $3,550,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Osbon Capital Management LLC purchased a new position in Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company during the fourth quarter worth $30,000. Maseco LLP boosted its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. grew its holdings in Eli Lilly and Company by 342.9% in the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Finally, Aventus Investment Advisors Inc. grew its holdings in Eli Lilly and Company by 270.0% in the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock valued at $34,000 after purchasing an additional 27 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LLY. Rothschild & Co Redburn lifted their price target on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Cantor Fitzgerald increased their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Bank of America raised their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Wolfe Research restated an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Finally, Royal Bank Of Canada upped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,292.18.

Eli Lilly and Company Stock Down 1.5%

Shares of NYSE:LLY opened at $1,212.96 on Wednesday. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.14 trillion, a P/E ratio of 40.70, a P/E/G ratio of 1.45 and a beta of 0.51. Eli Lilly and Company has a 52-week low of $629.40 and a 52-week high of $1,249.45. The stock’s fifty day simple moving average is $1,165.35 and its 200-day simple moving average is $1,049.90.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter last year, the business posted $6.31 EPS. The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 36.33 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 23.22%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. approved Lilly’s oral GLP-1 drug Foundayo for weight loss and weight maintenance in eligible adults. This is the pill’s first approval outside the United States and opens a large international market, although initial access will be primarily through private prescriptions while NHS coverage undergoes a cost-effectiveness review. Eli Lilly takes weight-loss pill battle global
• Positive Sentiment: Investors continue to cite Lilly’s strong second-quarter results as a foundation for further upside. Revenue increased 47.7% year over year to $22.97 billion, while earnings per share of $8.38 exceeded the $6.40 consensus estimate. Fiscal 2026 EPS guidance stands at $35.50–$36.50, supported by demand for Mounjaro, Zepbound and the broader obesity-drug portfolio. Eli Lilly Beat Big and Raised Guidance
• Positive Sentiment: Lilly participated in a $100 million financing for Absci, including a $40 million strategic investment. The partnership could provide exposure to Absci’s drug-discovery platform, though it is not expected to materially affect Lilly’s near-term financial results. Absci Reports Business Updates
• Neutral Sentiment: Analyst views remain broadly favorable, with recent price-target increases and a consensus “Moderate Buy” rating. However, the stock’s elevated valuation means additional gains may depend on continued earnings beats and successful international commercialization of Foundayo. Eli Lilly Fair Value Bump
• Negative Sentiment: Erste Group Bank lowered its 2026 EPS estimate to $34.93 from $35.34, below the company’s guidance range and the broader consensus estimate of $36.77. The reduction introduces a modest cautionary note after Lilly’s recent rally. Eli Lilly analyst estimates
• Negative Sentiment: Two executives reported stock sales totaling approximately $8.32 million. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which limits their value as evidence of weakening confidence, but the sales may still weigh marginally on sentiment. SEC Form 4 Filing

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.